Compare Core Scientific Inc (CORZ) vs Expensify Inc (EXFY) Price & Performance

Core Scientific (CORZ) trades at $15.36, down 3.64% with bearish technical signals despite strong analyst support. The company shows significant financial challenges with a -324.9% net income margin and consecutive quarterly earnings misses, though revenue growth from $319M to $440M is projected. Recent executive appointments and insider buying signal internal confidence amid the company's pivot toward AI data center infrastructure.

The stock presents a high-risk opportunity with Wall Street maintaining bullish price targets averaging $32.75, representing 113% upside potential. However, substantial losses, negative cash flow, and competitive pressures in the AI infrastructure space create significant execution risk. Investors must weigh analyst optimism against fundamental weaknesses and market volatility.

Expensify (EXFY) trades at $2.30, up 1.32% with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 and Q2 2026 earnings beats and positive operating cash flow of $20.09M in 2025. Recent business developments include AI-native ERP integrations and European card expansion, signaling growth initiatives. However, the stock carries a high P/E ratio of 258.82 and negative profitability metrics, presenting a mixed investment case.

The outlook remains cautiously optimistic with analyst consensus pointing to significant upside (target $13.75), but investors face risks from persistent net losses and competitive pressures. The key opportunity lies in the company's strategic pivot to AI-driven solutions and international expansion, though execution risks and valuation concerns warrant careful monitoring.